← Back to patent-cliff list
225Ac-LNC1011
Tier C — Watch / trade225Ac-LNC1011
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：PSMA
Indications (approved)：Castration-resistant prostate cancer, Prostate cancer
Regional status
US
-
EU
-
China
Phase II
2025-04-22
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 225Ac-LNC1011?
Approved indications include: Castration-resistant prostate cancer, Prostate cancer.
When does the 225Ac-LNC1011 patent expire?
No public expiry year is available for 225Ac-LNC1011 yet; this page updates once verified.
How do I get a quote for 225Ac-LNC1011 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30